KalVista Pharmaceuticals
NASDAQ · KALV·Cambridge, MA·Small-cap·Approved
Commercial-stage biotech focused on hereditary angioedema (HAE) and other plasma kallikrein-mediated diseases. Lead product EKTERLY (sebetralstat) is the first oral on-demand HAE therapy approved.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| KalVista Corporate Presentation March 2026 | Corporate overview | March 25, 2026 | 20 |